Brief introduction of AbbVie (China)

On 20 13 12, AbbVie was officially spun off from Abbott and listed on the NYSE independently. As a global research biopharmaceutical company, AbbVie has nearly 25,000 employees worldwide, and its products are sold to more than 65,438+070 countries. Headquartered in Shanghai 1, AbbVie China focuses on four major diseases: immunity, antivirus, nephropathy and anesthesiology. At the same time, AbbVie has cooperated closely with the medical community and government departments in China to carry out clinical research covering hepatitis C, tumor, immunology, neuroscience, pain, gynecological health and other fields.